The Drug Revolving Fund (DRF) is a sustainable financing mechanism designed to ensure continuous availability of essential medicines in public health facilities. Seed capital is provided initially to purchase a basic stock of drugs. As patients purchase these medicines, the cash generated is used exclusively to procure fresh stock, creating a self-sustaining cycle. In many Nigerian hospitals, the DRF solves the persistent challenge of out-of-stock syndrome, provided pricing and financial discipline are strictly maintained.
Accurate drug costing under the DRF requires identifying every expense tied to getting a medicine from the manufacturer to the patient's hands. Costs are broadly divided into two main groups:
Procurement expenses go far beyond the baseline invoice cost of pharmaceuticals. When ordering medicines, pharmacy managers must factor in port clearance fees, insurance during transit, and local haulage to the central medical store. In a decentralized supply system across various Nigerian states, bad roads and security escort fees can significantly drive up logistics costs. If these incidental expenses are omitted from the unit cost calculation, the revolving fund will slowly lose its purchasing power over successive cycles.
The mark-up is the percentage added to the total unit cost of a drug to arrive at the final retail selling price. This margin must be carefully calculated to cover inflation, minor losses from expired stock, wastage, and operational overheads. A common pitfall is setting the mark-up too low out of sympathy for patients, which cripples the fund's ability to replace commodities at rising market rates. Conversely, an excessively high mark-up defeats the public health goal of affordability.
Balancing financial sustainability with social equity requires deliberate pricing strategies. While profit-driven pharmacies charge uniform market rates, a DRF can implement tiered pricing or flat mark-ups across essential life-saving drugs. Subsidizing pediatric formulations or chronic disease medications like anti-hypertensives by placing lower mark-ups on them—while recovering the difference through higher-volume fast-moving items—ensures vulnerable populations are not priced out of essential healthcare.
Macroeconomic instability, particularly foreign exchange fluctuations and inflation, poses a severe threat to drug revolving funds in developing economies. Since most active pharmaceutical ingredients are imported, local currency devaluation instantly spikes replacement costs. To survive these shocks, managers must implement dynamic pricing reviews, maintain buffer stocks of fast-moving items, and avoid locking into rigid long-term fixed prices with suppliers during volatile periods.
Regular auditing and robust inventory control are the final safety nets of any DRF. Stockouts rarely happen overnight; they are usually preceded by poor record keeping, uncollected patient debts, pilferage, or failure to reconcile physical inventory with ledger accounts. Implementing strict stock control tools like ABC analysis (categorizing items by consumption value) and routine physical audits ensures transparency and preserves the revolving capital.